Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

182
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin,...
182
Allergic Reactions02:06

Allergic Reactions

33.7K
Overview
33.7K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

2.2K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.2K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
Allergic Drug Reactions01:27

Allergic Drug Reactions

1.6K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.6K
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

1.4K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply.

The Journal of allergy and clinical immunology·2026
Same author

Updates on Kinase Inhibitors in Allergy.

The journal of allergy and clinical immunology. In practice·2025
Same author

Engrafted NSG-SGM3 humanized mice spontaneously produce human immunoglobulins including IgE.

Frontiers in immunology·2025
Same author

The Bruton tyrosine kinase inhibitor acalabrutinib aborts ongoing acute food-induced anaphylactic reactions in humanized mice.

The Journal of allergy and clinical immunology·2025
Same author

Current and future landscape of Bruton tyrosine kinase inhibitors in allergy.

The Journal of allergy and clinical immunology·2025
Same author

Defining Optimal Basophil Passive Sensitisation Parameters.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2024
Same journal

Anaphylaxis: State-of-the-Art.

Immunology and allergy clinics of North America·2026
Same journal

Upending Impending Doom.

Immunology and allergy clinics of North America·2026
Same journal

Mast Cell Activation Syndrome and Mimickers.

Immunology and allergy clinics of North America·2026
Same journal

Hereditary Alpha-Tryptasemia (HαT) as a Risk Modifier for Severe Anaphylaxis.

Immunology and allergy clinics of North America·2026
Same journal

Novel Epinephrine Delivery Devices.

Immunology and allergy clinics of North America·2026
Same journal

Venom Anaphylaxis.

Immunology and allergy clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Apr 5, 2026

Measuring Local Anaphylaxis in Mice
07:49

Measuring Local Anaphylaxis in Mice

Published on: October 14, 2014

20.2K

Emerging Therapies for Anaphylaxis.

Melanie C Dispenza1

  • 1Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, USA.

Immunology and Allergy Clinics of North America
|April 3, 2026
PubMed
Summary
This summary is machine-generated.

Novel therapies are emerging to treat anaphylaxis by targeting its various underlying mechanisms. These innovative treatments, including tyrosine kinase inhibitors and new antibody-based therapies, are in clinical development for prevention and management.

Keywords:
AnaphylaxisBruton tyrosine kinaseChronic urticariaFood allergyIgEKITKinase

More Related Videos

Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

9.9K
Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

4.1K

Related Experiment Videos

Last Updated: Apr 5, 2026

Measuring Local Anaphylaxis in Mice
07:49

Measuring Local Anaphylaxis in Mice

Published on: October 14, 2014

20.2K
Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

9.9K
Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

4.1K

Area of Science:

  • Immunology
  • Pharmacology
  • Allergy and Immunology

Background:

  • Anaphylaxis is a severe allergic reaction with diverse underlying causes.
  • Current treatments focus on symptom management, but novel approaches are needed.

Purpose of the Study:

  • To review emerging therapies for anaphylaxis prevention and treatment.
  • To discuss novel therapeutic targets and agents in clinical development.

Main Methods:

  • Review of current clinical research and development in anaphylaxis therapeutics.
  • Identification of novel drug classes and targets.

Main Results:

  • Several novel therapeutic strategies are under investigation.
  • These include tyrosine kinase inhibitors, allergen-specific blocking antibodies, and monoclonal antibodies targeting KIT or inhibitory receptors.

Conclusions:

  • New therapies targeting specific anaphylaxis pathways show promise.
  • These agents may offer improved prevention and treatment options for anaphylaxis.